0001104659-13-081325.txt : 20131105 0001104659-13-081325.hdr.sgml : 20131105 20131105204909 ACCESSION NUMBER: 0001104659-13-081325 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20131105 FILED AS OF DATE: 20131105 DATE AS OF CHANGE: 20131105 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 508-975-4820 MAIL ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Shacham Sharon CENTRAL INDEX KEY: 0001588438 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 131194398 MAIL ADDRESS: STREET 1: C/O KARYOPHARM THERAPEUTICS INC. STREET 2: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 3 1 a3.xml 3 X0206 3 2013-11-05 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001588438 Shacham Sharon C/O KARYOPHARM THERAPEUTICS INC. 2 MERCER ROAD NATICK MA 01760 0 1 0 0 C.S.O & Pres. of Res & Develop Common Stock 1001713 D Common Stock 620771 I By Spouse Stock Option (right to buy) 4.75 2023-09-02 Common Stock 480303 D Stock Option (right to buy) 0.03 2020-10-21 Common Stock 110713 D Stock Option (right to buy) 0.03 2020-11-01 Common Stock 23567 D Stock Option (right to buy) 0.26 2021-12-14 Common Stock 39393 D Stock Option (right to buy) 0.26 2021-12-14 Common Stock 30303 D Stock Option (right to buy) 0.26 2021-12-14 Common Stock 42424 I By Spouse Stock Option (right to buy) 0.26 2021-12-14 Common Stock 33333 I By Spouse Stock Option (right to buy) 4.75 2023-09-02 Common Stock 480303 I By Spouse Series A Convertible Preferred Stock Common Stock 132575 I By Spouse Reflects a 1-for-3.3 reverse stock split effected on October 25, 2013. This option was granted on September 3, 2013. The shares underlying this option vest as to 25% of the shares on September 3, 2014, with the remaining 75% vesting in 36 equal monthly installments thereafter. This option was granted on October 21, 2010. The shares underlying this option vest as to 25% of the shares on October 22, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter. The option is subject to an early exercise provision, which allows the reporting person to exercise the option as to the unvested shares (in addition to the vested shares), subject to the Issuer' right to repurchase any vested or unvested shares. This option was granted on November 1, 2010. The shares underlying this option vest as to 25% of the shares on October 22, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter. The option is subject to an early exercise provision, which allows the reporting person to exercise the option as to the unvested shares (in addition to the vested shares), subject to the Issuer' right to repurchase any vested or unvested shares. This option was granted on December 14, 2011. The shares underlying this option vest as to 25% of the shares on December 12, 2012, with the remaining 75% vesting in 36 equal monthly installments thereafter. This option was granted on December 14, 2011. The shares underlying this option vest as to 25% of the shares on June 18, 2013, with the remaining 75% vesting in 36 equal monthly installments thereafter. This option was granted on December 14, 2011. The shares underlying this option vest as to 25% of the shares on December 12, 2012, with the remaining 75% vesting in 36 equal monthly installments thereafter. This option was granted on December 14, 2011. The shares underlying this option vest as to 25% of the shares on June 18, 2013, with the remaining 75% vesting in 36 equal monthly installments thereafter. This option was granted on September 3, 2013. The shares underlying this option vest as to 25% of the shares on September 3, 2014, with the remaining 75% vesting in 36 equal monthly installments thereafter. The Series A Convertible Preferred Stock is convertible into Common Stock on a 1-for-3.3 basis into the number of shares of Common Stock as shown in column 3 at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares have no expiration date. /s/ Sharon Shacham 2013-11-05 EX-24.1 2 ex-24d1.htm EX-24.1 Exhibit 24

Exhibit 24.1

 

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

 

Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Paul Brannelly, Joshua D. Fox and Christopher Primiano, signing singly and each acting individually, as the undersigned’s true and lawful attorney-in-fact with full power and authority as hereinafter described to:

 

(1)                                 execute for and on behalf of the undersigned, in the undersigned’s capacity as an officer and/or a director of Karyopharm Therapeutics Inc. (the “Company”), Forms 3, 4, and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder (the “Exchange Act”);

 

(2)                                 do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to prepare, complete and execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or amendments thereto, and timely deliver and file such form with the United States Securities and Exchange Commission (the “SEC”) and any stock exchange or similar authority, including without limitation the filing of a Form ID or any other application materials to enable the undersigned to gain or maintain access to the Electronic Data Gathering, Analysis and Retrieval system of the SEC;

 

(3)                                 seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information regarding transactions in the Company’s securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such third party to release any such information to the herein appointed attorney-in-fact and approves and ratifies any such release of information; and

 

(4)                                 take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.

 

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming nor relieving, nor is the Company assuming nor relieving, any of the undersigned’s responsibilities to comply with Section 16 of the Exchange Act.  The undersigned acknowledges that neither the Company nor the foregoing attorneys-in-fact assume (i) any liability for the undersigned’s responsibility to comply with the requirement of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act.

 

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with the SEC with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

 

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 5th day of November, 2013.

 

 

/s/ Sharon Shacham

 

Sharon Shacham, Ph.D., M.B.A.